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1. INTRODUCTION {#pa2280-sec-0001}
===============

The critical roles of laboratory testing cannot be overemphasised in the prevention and management of infectious diseases outbreak (Bedford et al., [2020](#pa2280-bib-0006){ref-type="ref"}). Laboratory professionals play essential roles in diagnosis, epidemiologic surveillance and monitoring of patients with suspected and established cases of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, which is the virus strain that causes coronavirus disease (COVID‐19; Lippi & Plebani, [2020](#pa2280-bib-0012){ref-type="ref"}). The effort of the laboratory professionals and the country strategies in the containment, risk analysis, structures and features of the novel coronavirus deserves understudying for some reasons. For a disease condition that has been categorised as transmitting from human‐to‐human, there is a greater need for quick detection and subsequent isolation in order to flatten the curve and reduce the strain on the medical facilities that are largely dilapidated in Africa. In other climes, clustering analysis is an essential pre‐requisite to epidemic management and care surveillance aimed at the efficacy of treatment procedures. By identifying the cluster or group of society that are most vulnerable and susceptible to viral loads induced by contagion with pathogens from the virus, further care and treatment procedure can be established. In recent findings, O, rhesus D positive (+) individuals are reported to have more excellent antibodies to resist infestation of coronavirus. By assessing the laboratory response to COVID‐19 in Africa, this study aims to establish the depth of COVID‐19 growth and subsequent policy recommendations, particularly as it relates to easing lockdown directives in place in most Africa countries. It informs the government and stakeholders restrictive measures and the desire to return to a healthy life.

COVID‐19 is an infectious disease of the novel coronavirus. The COVID‐19 pandemic is the third eventful zoonotic coronavirus disease outbreak in 20 years (Mackenzie & Smith, [2020](#pa2280-bib-0014){ref-type="ref"}). The infectious disease succeeded in the Severe Acute Respiratory Syndrome outbreak (SARS) in 2002--2003 and Middle East Respiratory Syndrome (MERS) outbreak in 2012 (Poon & Peiris, [2020](#pa2280-bib-0022){ref-type="ref"}). The current pandemic emerged in Wuhan, China and has spread rapidly around the world (Adnan, Khan, Kazmi, Bashir, & Siddique, [2020](#pa2280-bib-0003){ref-type="ref"}) with an estimated over 3 million cases globally with 259,474 deaths, above 1.6 million cases in Europe with around 152,179 deaths, over 634,000 cases in Asia with around 21,501 deaths (WHO, [2020a](#pa2280-bib-0031){ref-type="ref"}).[^1^](#pa2280-note-0001){ref-type="fn"} We observed heterogeneous approaches in the laboratory responses across nations in Africa. These variations in the laboratory responses of the containment of COVID‐19 were primarily to aid early detection of the virus for prompt isolation, management of the infected individuals, and prevention of community transmission or sporadic cases of the virus (Loeffelholz & Tang, [2020](#pa2280-bib-0013){ref-type="ref"}).

The laboratory response of this novel virus comprises of a collection of appropriate samples from patients who meet up with suspect case definitions (as contained in the WHO guidelines) and selection of accurate laboratory methods (WHO, [2020b](#pa2280-bib-0032){ref-type="ref"}). The SARS‐CoV‐2 has been detected from a multifarious of upper and lower respiratory sources, including throat, nasopharyngeal, sputum, and so on (WHO, [2020c](#pa2280-bib-0033){ref-type="ref"}). A number of laboratory methods have been adopted in Africa for COVID‐19 testing, and they include the Molecular test method of Nucleic Acid Amplification Tests (NAAT), Serological testing, and Viral Genome Sequencing (Abdullahi et al., [2020](#pa2280-bib-0002){ref-type="ref"}; Loeffelholz & Tang, [2020](#pa2280-bib-0013){ref-type="ref"}). Amid these global health challenges which have caused panorama of problems in global medical supply chains, African countries have no options than to result to indigenous (herbal solutions) ways of combatting the pandemic, although in line with international practices. In this study, an attempt is made to unravel the underlying testing procedures adopted by high incidence African nations (Nigeria, South Africa, Egypt, Ghana, Morocco, Algeria) with attendant efficacy relative to their population density. Policy measures, particularly alternative approaches that could induce greater efficiency in the laboratory reactions to the growth curve of COVID‐19, are discussed in the study. In Figures [1](#pa2280-fig-0001){ref-type="fig"} and [2](#pa2280-fig-0002){ref-type="fig"}, we reported the spatial density of COVID‐19 confirmed cases and attributable deaths across African states. Having introduced the study, the other section of the study are as follows; 2.0 gives Nigeria\'s laboratory response to COVID‐19, 3.0 gives South Africa\'s laboratory response to COVID‐19, 4.0 gives Egypt\'s laboratory response to COVID‐19, 5.0 gives Algeria\'s laboratory response to COVID‐19, 6.0 gives the Morrocco\'s laboratory response to COVID‐19, 7.0 gives Ghana\'s laboratory response to COVID‐19, while 8.0 concludes.

![African countries COVID‐19 cases](PA-9999-e2280-g001){#pa2280-fig-0001}
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2. NIGERIA\'S LABORATORY RESPONSE TO COVID‐19 {#pa2280-sec-0002}
=============================================

Nigeria has recorded 3,526 confirmed cases of COVID‐19 cases with 107 deaths as of 8th May 2020. So far, 23,835 samples were taken and tested (NCDC, [2020c](#pa2280-bib-0020){ref-type="ref"}), which constitute less than 1% tests of the total population of around 200million (World bank, [2018](#pa2280-bib-0030){ref-type="ref"}). The Nigeria Centre for Disease Control (NCDC) is the federal government agency with the authorisation for national preparedness, detection and response to infectious disease outbreaks (NCDC, [2020a](#pa2280-bib-0018){ref-type="ref"}). The agency performs the role of coordination of laboratory services in response to the COVID‐19 outbreak with the establishment of the laboratory network, which comprises 21 laboratories across states in Nigeria (NCDC, [2020b](#pa2280-bib-0019){ref-type="ref"}). NCDC partnered with the Medical Laboratory Science Council of Nigeria (MLSCN) to develop a national strategy for COVID‐19 testing, which contained the laboratory techniques which are currently in use and the future ones they hope to adopt to increase access to testing (MLSCN, [2020](#pa2280-bib-0015){ref-type="ref"}). Molecular method of reverse transcription polymerase chain reaction (RT‐PCR) has been adopted as the gold standard for accurate testing of the pandemic in Nigeria with minimum sensitivity and specificity of 99% each (MLSCN, [2020](#pa2280-bib-0015){ref-type="ref"}).

In the RT‐PCR method, a reverse transcriptase approach was employed to convert the RNA template into a complementary DNA (cDNA) with subsequent use of the cDNA as a template for exponential amplification using PCR (Abdullahi et al., [2020](#pa2280-bib-0002){ref-type="ref"}; Udugama et al., [2020](#pa2280-bib-0025){ref-type="ref"}). In the RT‐PCR procedure, we confirm the existence of SARS‐CoV‐2 in a patient when the assay is positive. It should be noted that a laboratory outcome showing negative findings does not entirely rule out the presence of coronavirus in a patient (MLSCN, [2020](#pa2280-bib-0015){ref-type="ref"}). By intuition, a negative laboratory finding premediated on a suspected patient implies that the viral density was well below the detection point. In other climes, an RT‐PCR assay laboratory finding could show adverse outcomes if the infection has run its cause leading to viral clearance (MLSCN, [2020](#pa2280-bib-0015){ref-type="ref"}). NCDC also developed a framework for incorporation of up to high throughput HIV molecular testing laboratories, which are capable of raising national capacity to a minimum of 5,000 tests per day (NCDC, [2020a](#pa2280-bib-0018){ref-type="ref"}). 41 GeneXpert machines have also been slated for incorporation into the laboratory network with a capacity of further increasing national capacity to 7,000 tests per day (NCDC, [2020b](#pa2280-bib-0019){ref-type="ref"}). Nigeria through a collaboration between Lagos State Ministry of Health, Nigeria Centre for Disease Control (NCDC) African Centre of Excellence for the Genomics of Infectious Disease (ACEGID), College of Medicine University of Lagos/Lagos University Teaching Hospital (LUTH), Nigerian Institute of Medical Research (NIMR) published the first genome sequence of SARS‐CoV‐2 from Africa from the first confirmed case of COVID‐19 in the country (NCDC, [2020c](#pa2280-bib-0020){ref-type="ref"}).

Serology testing helps to investigate the current pandemic and retrospective assessment of the extent of the outbreak. Nigeria\'s NCDC plan to look into the relevance of this antigen and antibody tests in the future to understand the rate of infectivity of the virus in the country. However, this method is subject to validation by the Medical Laboratory Science Council of Nigeria (MLSCN) before it can be deployed for routine testing in Nigeria (NCDC, 2020). MLSCN specifies that the sensitivity and specificity of this method of the assay must not be less than 95% with RT‐PCR as a standard before approval can be given for its complimentary usage with other molecular methods (MLSCN, [2020](#pa2280-bib-0015){ref-type="ref"}). Nigeria\'s Laboratory capacity for COVID‐19 testing is being worked on to carry out 2 million tests in the next 3 months by the utilisation of the maximum capacity of various laboratories within its network to improve the nation\'s undesirable testing coverage among countries with over 1,000 cases across Africa (NCDC, [2020a](#pa2280-bib-0018){ref-type="ref"}).

3. SOUTH AFRICA\'S LABORATORY RESPONSE TO COVID‐19 {#pa2280-sec-0003}
==================================================

Confirmed cases of COVID‐19 in South Africa stand at 8,895 with 178 mortalities as the time of writing (8th May 2020). A total of 307,752 tests has been done in all provinces of the country, but less than 1% of the South African population, which is over 57 million (Statistics South Africa, [2020](#pa2280-bib-0024){ref-type="ref"}), has been covered in COVID‐19 testing (National Department of Health, [2020](#pa2280-bib-0016){ref-type="ref"}). Testing coordination for the novel coronavirus in South Africa is led by the National Health Laboratory Service (NHLS), which is the biggest diagnostic pathology service provider with roles of assisting the national and provincial health authorities in healthcare delivery in South Africa (NHLS, [2020](#pa2280-bib-0017){ref-type="ref"}). 80% of the South African population is served through the National Network of Laboratories. NHLS has National Institute for Communicable Diseases (NICD), National Institute for Occupational Health (NIOH), and the South African Vaccine Producers (SAVP) as subsidiaries (NHLS, [2020](#pa2280-bib-0017){ref-type="ref"}).

NHLS has 11 laboratories in nine provinces across South Africa designated for Coronavirus testing (NHLS, [2020](#pa2280-bib-0017){ref-type="ref"}). NHLS procured 67 mobile sampling and testing units which were deployed nationwide to join 180 testing sites and 320 testing units already in place across the country. NHLS is currently using the molecular method of RT‐PCR for COVID testing across its network of regional laboratories and mobile testing sites. South Africa planned to deploy the mobile laboratories for rapid serological kits for population surveillance when they are available in the country (UN, [2020c](#pa2280-bib-0028){ref-type="ref"}). National Institute of Communicable Diseases (NICD) partnered with the South African National Bioinformatics Institute at the University of Western Cape to publish a complete genome sequence of SARS‐CoV‐2 isolated from a South African patient with coronavirus disease 2019 who had returned to South Africa after travelling to Italy (Allam et al., [2020](#pa2280-bib-0004){ref-type="ref"}). With this, South Africa is on the verge of increasing her current 5,000 tests for COVID‐19 daily by six‐folds (National Department of Health, [2020](#pa2280-bib-0016){ref-type="ref"}).

4. EGYPT\'S LABORATORY RESPONSE TO COVID‐19 {#pa2280-sec-0004}
===========================================

Egypt has recorded 8,478 COVID‐19 laboratory‐confirmed cases and 503 deaths from the novel Coronavirus disease (WHO, [2020a](#pa2280-bib-0031){ref-type="ref"}) as at the time of writing 8th May 2020. COVID‐19 tests have been done on 90,000 samples (Worldometer, [2020](#pa2280-bib-0035){ref-type="ref"}) out of 102 million populace a share representation of less than 1% of the country population (UN, [2020b](#pa2280-bib-0027){ref-type="ref"}). COVID‐19 outbreak management, testing, and control are coordinated through the Ministry of health and population of Egypt (MOHP). Combined method of RT‐PCR and serological use of a rapid diagnostic test for anti‐severe acute respiratory syndrome coronavirus 2 IgM and IgG are deployed in Egypt (Hassany, Abdel‐Razek, Asem, AbdAllah, & Zaid, [2020](#pa2280-bib-0009){ref-type="ref"}). RT‐PCR method is used across the laboratory network on symptomatic patients and contacts of confirmed cases while screening at points of entry are done with Rapid diagnostic kits (Hassany et al., [2020](#pa2280-bib-0009){ref-type="ref"}). Egypt\'s laboratory network includes 17 laboratories with the plan to augment with another four and University hospital laboratories, which can increase national capacity to 200,000 in a total testing frame (WHO, 2020d).

5. ALGERIA\'S LABORATORY RESPONSE TO COVID‐19 {#pa2280-sec-0005}
=============================================

Algeria has recorded 5,182 confirmed cases of COVID 19 cases with 483 deaths as of 8th May 2020 (WHO, [2020a](#pa2280-bib-0031){ref-type="ref"}) having conducted tests on 6,500 samples, which constitute 0.01% of the total population of over 42 million (UN, [2020a](#pa2280-bib-0026){ref-type="ref"}). Laboratory response to COVID‐19 management in Algeria is anchored by the Institut Pasteur Algeria (IPA). The Institut Pasteur Algeria (IPA) based out of capital Algiers was testing samples from across the country (WHO, 2020e). The Institut Pasteur Algeria (IPA) also invited hospital laboratories with the equipment to get involved in screening for the virus to meet the demand for more tests (Kezzal, [2020](#pa2280-bib-0011){ref-type="ref"}). RT‐PCR is the method of choice for testing for the SARS COV 2 virus in Institut Pasteur Algeria (IPA) Laboratory Network (Kezzal, [2020](#pa2280-bib-0011){ref-type="ref"}). IPA laboratory network is being expanded to accommodate other annexes in Oran, Constantine and Ouargla, which is capable of increasing the testing capacity to 400 tests per day.

6. MORROCCO\'S LABORATORY RESPONSE TO COVID‐19 {#pa2280-sec-0006}
==============================================

Confirmed cases of COVID‐19 in Morocco stand at 5,548, with 183 deaths (WHO, [2020a](#pa2280-bib-0031){ref-type="ref"}) as at the time of writing (8th May 2020). A total of 42,112 tests has been carried out across the country, but just 0.1% of the Morocco population has been covered in COVID‐19 laboratory testing (Worldometer, [2020](#pa2280-bib-0035){ref-type="ref"}). Laboratory testing for SARS COV 2 virus started in Morocco in The National Institute of Hygiene in Rabat (INH), the Pasteur Institute in Casablanca, and the Laboratory of the Mohamed V military training hospital in Rabat with a combined daily capacity of 200--300 tests. An effort is on to include University Hospital Centres network in order to increase accessibility to the COVID‐19 testing with procurements of tens of thousands of Reverse transcription‐polymerase chain reaction (RT‐PCR) kits (Amuedo, [2020](#pa2280-bib-0005){ref-type="ref"}). Also, Moroccan health authorities are planning to diversify its laboratory expertise by adopting a more straightforward diagnostic techniques for more comprehensive national coverage and expansion of the COVID‐19 laboratory network without the inclusion of private laboratories for the time being (Kasraoui, [2020](#pa2280-bib-0010){ref-type="ref"}). Reverse transcription‐polymerase chain reaction (RT‐PCR) is the only method of analysis currently in use for COVID‐19 testing in the country. Morocco is currently deploying all machinery to achieve 10,000 tests daily capacity to curb the spread of the virus in the Arab peninsula (Amuedo, [2020](#pa2280-bib-0005){ref-type="ref"}).

7. GHANA\'S LABORATORY RESPONSE TO COVID‐19 {#pa2280-sec-0007}
===========================================

Ghana has recorded 3,091 confirmed cases of COVID‐19 cases with 18 deaths as of 8th May 2020 (WHO, [2020a](#pa2280-bib-0031){ref-type="ref"}) having conducted tests on 149,948 samples, which constitute 0.5% of the total population of 29 million (Ghana Health Services, [2020](#pa2280-bib-0007){ref-type="ref"}). The novel Coronavirus testing started in Ghana in The Noguchi Memorial Institute for Medical Research (NMIMR), a medical research institute of the University of Ghana. NMIMR is the primary testing facility accounting for 80% of the COVID‐19 tests done in the country (Abbey, Adu‐Danso, & Aryeetey, [2020](#pa2280-bib-0001){ref-type="ref"}). Noguchi Memorial Institute for Medical Research along with Kumasi Centre for Collaborative Research (KCCR) was initially designated for testing the virus before other testing centres like National Public Health Reference Laboratories, Council for Scientific and Industrial Research (CSIR), and so on was added to the laboratory network (Ghana News Agency, [2020](#pa2280-bib-0008){ref-type="ref"}). Ghana government has invested in Reverse transcription‐polymerase chain reaction (RT‐PCR) technology in these laboratories to expand its testing capacity and increase access for the Ghanaian populace.

Ghana has also adopted the pooled testing algorithm for the RT‐PCR method to increase its laboratory network efficiency and increase cost‐saving measures. One thousand samples are grouped into 10, and 100 pools test are done at a time. If there is a positive result in a mini‐pool, individual testing is then carried out on the original samples that were put in the pool. In the case of a negative result, all included samples have a negative result, but this method is capable of giving false‐negative results in the large pool of samples (Shani‐Narkiss, Gilday, Yayon, & Landau, [2020](#pa2280-bib-0023){ref-type="ref"}). Almost 130,000 tests have been carried out in all provinces making Ghana the second country after South Africa, which has done most tests in Africa (Ghana Health Services, 2020). An effort is also in place to add 100 Regional and District Tuberculosis Gene Expert Laboratories, which will make each region have at least one testing centre for COVID‐19 screening (Ghana News Agency, [2020](#pa2280-bib-0008){ref-type="ref"}).

8. CONCLUSION {#pa2280-sec-0008}
=============

Despite the rampaging nature of coronavirus disease (COVID‐19) across the world, laboratory responses in Africa\'s high incidence nations have remained heterogeneous and inadequate in the fight against the wide‐spreading infectious disease. Across cities and regions in Africa, various forms of laboratory response to the identification, epidemiological surveillance, and subsequent management of patients include RT‐PCR, Serological testing, and viral genome sequencing. The various laboratory testing procedures are discussed in their regional specific domains. Beyond the identifications, we advanced arguments for the efficacy of each of these tests and discuss alternative and efficient laboratory measures that could aid the fight against COVID‐19 in Africa. We found that these high incidence Africa countries adopt RT PCR majorly with slight modification in sampling method, mode of deployment and pre‐analytical conditions. However, the number of tests which stand at an average percentage of 1% of their respective population indicates sub‐optimal success recorded in the fight against COVID‐19 in Africa. To prevent the emergence of new cases and abate sporadic community transmission that could stretch the capacity of the healthcare facilities in Africa, there is a need for increase testing capacity such that we can detect early and isolate affected patients. We recommend that greater and improved health care financing, adoption of a mobile testing laboratory to make an inroad into rural communities, re‐assessment of the remuneration and incentives packages to be extended to laboratory professionals such that they do not surrender the fight against this fast‐spreading and deadly diseases. In other climes, the African manufacturing sector should do more in terms of the development of homemade solutions to complement existing health infrastructures at this time of the global pandemic.

In Figure [3](#pa2280-fig-0003){ref-type="fig"}, we reported the laboratory testing conducted in the six high incidence countries in Africa based on indices in Table [1](#pa2280-tbl-0001){ref-type="table"} following.

![Laboratory testing conducted in six high incidence African countries (as at 8th May 2020)](PA-9999-e2280-g003){#pa2280-fig-0003}

###### 

Test per population in high incidence African countries

  Countries      Confirmed cases   Death cases   Total number recoveries   Number of laboratory test carried out so far   Population density (in millions)   Test per population percentage
  -------------- ----------------- ------------- ------------------------- ---------------------------------------------- ---------------------------------- --------------------------------
  Nigeria        4,641             150           902                       27,078                                         200                                0.01
  South Africa   10,652            206           4,357                     356,067                                        57                                 0.62
  Egypt          9,746             533           2,172                     90,000                                         102                                0.09
  Algeria        5,891             507           2,841                     6,500                                          42                                 0.02
  Morocco        6,281             188           2,811                     68,980                                         36                                 0.19
  Ghana          4,700             22            323                       160,501                                        29                                 0.55

The pictorial representation and the tabular information apparently reveals that in all high incidence countries in Africa, less than 1% of the total population has been tested. The implications of this are many, and the consequences are immense (Adekunle, Onanuga, Akinola & Olakitan, 2020). A large number of the populace who could have been in contact with an infected person has not been detected. Thus, scaling up the risk of community transmission that could eventually strain already dilapidated and inadequate health facilities in Africa. It remains to be seen what the dimension of COVID‐19 spread could take in Africa in the coming days and months. We reported test per population in all African countries in Table [2](#pa2280-tbl-0002){ref-type="table"}.

###### 

Test per population in African countries

  Countries               Confirmed cases   Death cases   Recoveries   No. of tests   Population (in millions)   Test per population percentage
  ----------------------- ----------------- ------------- ------------ -------------- -------------------------- --------------------------------
  Nigeria                 4,641             150           902          27,078         200,963,599                0.01
  South Africa            10,652            206           4,357        356,067        58,558,270                 0.61
  Egypt                   9,746             533           2,172        90,000         100,388,073                0.09
  Algeria                 5,891             507           2,841        6,500          43,053,054                 0.02
  Morocco                 6,281             188           2,811        68,980         36,471,769                 0.19
  Ghana                   4,700             22            323          160,501        30,417,856                 0.53
  Senegal                 1,886             19            715          18,969         16,296,364                 0.12
  Ivory Coast             1,730             21            818          13,663         25,716,544                 0.05
  Djibouti                1,227             3             872          15,790         973,560                    1.62
  Tunisia                 1,032             45            700          33,266         11,694,719                 0.28
  Niger                   832               46            637          5,598          23,310,715                 0.02
  Mali                    712               39            377          2,172          19,658,031                 0.01
  Mayotte                 1,023             11            492          4,000          266,150                    1.50
  Kenya                   700               33            251          32,938         52,573,973                 0.06
  Gabon                   802               9             127          5,337          2,172,579                  0.25
  Mauritius               332               10            322          69,773         1,269,668                  5.50
  Equatorial Guinea       439               4             13           854            1,355,986                  0.06
  Rwanda                  285               0             150          42,805         12,626,950                 0.34
  Guinea Bissau           761               3             26           1,500          1,920,922                  0.08
  Cape Verde              260               2             58           791            549,935                    0.14
  Madagascar              186               0             101          3,968          26,969,307                 0.01
  Ethiopia                250               5             105          36,624         112,078,730                0.03
  Togo                    181               11            89           10,561         8,082,366                  0.13
  Zambia                  267               7             117          10,270         17,861,030                 0.06
  Eswatini                175               2             28           714            1,148,130                  0.06
  Benin                   319               2             62           22,808         11,801,151                 0.19
  Uganda                  121               0             55           58,608         44,269,594                 0.13
  Mozambique              103               0             34           4,173          30,366,036                 0.01
  CAR                     143               0             10           3,498          4,745,185                  0.07
  Libya                   64                3             28           3,253          6,777,452                  0.04
  South Sudan             156               0             2            1,247          11,062,113                 0.01
  Malawi                  57                3             24           1,337          18,628,747                 0.01
  Angola                  45                2             13           3,000          31,825,295                 0.01
  Zimbabwe                36                4             9            20,537         14,645,468                 0.14
  Botswana                24                1             12           9,540          2,303,697                  0.41
  Gambia                  22                1             10           1,238          2,347,706                  0.05
  Sao Tome and Principe   208               5             4            175            215,056                    0.08
  Namibia                 16                0             11           1,543          2,494,530                  0.06
  Burundi                 15                1             7            284            11,530,580                 0.00
  Mauritania              8                 1             6            2,015          4,525,696                  0.04
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